Greetings!

This message includes:
  • information from VDH on a new survey to help with planning for COVID-19 vaccine boosters and third doses; and
  • a Q&A on what we know so far about boosters versus additional doses for immunocompromised.

Sincerely,

April Payne, MBA, LNHA
Chief Quality & Regulatory Affairs Officer
Executive Director of VCAL
Virginia Health Care Association | Virginia Center for Assisted Living 
VDH Long Term Care Facility Vaccine Access Survey

VDH is trying to better understand how many additional COVID-19 vaccines will be needed in long term care facilities (LTCFs) once the Advisory Committee on Immunization Practices (ACIP) and CDC guidelines for boosters and third doses are released. These data are crucial as they will help VDH plan accordingly based on the vaccine needs and enable VDH to successfully support LTCFs in ensuring they have access to COVID vaccines.
VDH is requesting that all survey responses be completed by close of business on September 10.

If you are part of a CCRC/multicare facility, please fill out separate forms for each entity.

If you have questions about the survey, please reach out to Mounika Bazar or Sumaia Kamal.
Q&A: Boosters vs. Additional Doses for Immunocompromised

AHCA/NCAL has prepared a Q&A to provide more information on the plan for booster shots for individuals who have been vaccinated with the Pfizer-BioNTech COVID-19 vaccine or the Moderna COVID-19 vaccine. Questions also cover what is known about the use of additional doses for certain immunocompromised individuals.
 
What is the difference between a booster and an additional dose for the immunocompromised?  

A “booster” is given to someone who created a normal immune response from the initial series, but that immune response waned over time. So, a booster is given at a specific time frame based on evidence that shows immunity is waning. US Department of Health and Human Services (HHS) announced that it is preparing to deliver boosters after eight months of the final dose. This dose is not considered a part of the primary series. 

It is important to note that the FDA and the CDC’s Advisory Committee on Immunization Practices (ACIP) must first meet to approve the vaccine booster before it can be recommended for use.  

The additional dose for the immunocompromised is being recommended due to evidence that the initial immune response in these individuals was not adequate. The ACIP-reviewed data that indicated that individuals with moderate to severe immunosuppression do not create an adequate immune response after the initial two-dose series of the Pfizer and Moderna, and as a result, it is recommending a third dose as part of the primary series at least 28 days after completion of the first two doses.  
 
Who is considered immunocompromised? 

People with moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments are eligible to receive an additional dose. These conditions and treatments include but are not limited to: 
  • active treatment for solid tumor and hematologic malignancies 
  • receipt of solid-organ transplant and taking immunosuppressive therapy 
  • receipt of CAR-T-cell or hematopoietic stem cell transplant (within two years of transplantation or taking immunosuppression therapy) 
  • moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome) 
  • advanced or untreated HIV infection 
  • active treatment with high-dose corticosteroids (i.e., ≥20mg prednisone or equivalent per day), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory. 

More information is available here
 
Who should receive a booster and when? 

Pending approval by the FDA and the CDC’s ACIP, all individuals who have been vaccinated with the Pfizer or Moderna should receive a booster shot eight months after the second dose. The recommended time frame will be confirmed by the FDA and ACIP, but HHS is preparing for a time frame of eight months after receipt of the final dose.
 
Does this change the definition of “fully vaccinated”? 

No, the definition of fully vaccinated has not changed. As of now, the definition of fully vaccinated remains as two weeks after completion of the series (one or two doses).
 
What about people who received the Johnson and Johnson/Janssen vaccine? 

Right now, individuals who have received the J&J/Janssen vaccine are not recommended to get a third shot or an additional shot for the immunocompromised. The CDC and FDA are actively reviewing data from the J&J vaccine to see if there is any waning immunity and will be making recommendations once enough data is available.
 
What should I do next? 

Providers can take a few key steps to start preparing.  
  • Identify residents (and/or their representatives) who meet the eligibility criteria for being immunocompromised and offer them the third dose or to talk to their physician about receiving a third dose of an mRNA vaccine. Individuals can self-attest and receive the additional dose wherever vaccines are offered. 
  • Talk to your LTC pharmacy about preparing to deliver the booster shot, once available. If you do not have a contractual arrangement with an LTC pharmacy, we recommend you talk to your state health department or seek a partner through the Federal. 
  • Continue to encourage uptake among residents and staff. Check out the #GetVaccinated campaign website for resources.
Quick Links
www.vhca.org | (804) 353-9101 | Calendar of Events